查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1928582

一次性自動切片檢查設備市場（按類型、引導類型、應用和最終用戶分類），全球預測，2026-2032年

Disposable Fully Automatic Biopsy Device Market by Type, Guidance Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年一次性自動切片檢查設備市場價值為 3.0221 億美元，預計到 2026 年將成長至 3.3008 億美元，預計到 2032 年將達到 4.6593 億美元，複合年成長率為 6.37%。

關鍵市場統計數據
基準年 2025 3.0221億美元
預計年份：2026年 3.3008億美元
預測年份 2032 4.6593億美元
複合年成長率 (%) 6.37%

微創診斷時代一次性全自動切片檢查設備市場趨勢策略概述

一次性全自動切片檢查設備已成為現代影像導引微創診斷的關鍵基礎技術。隨著全球醫療系統致力於更早發現疾病、縮短手術時間並提高患者安全性，這些設備正在革新臨床醫生從乳房、肝臟、肺臟和前列腺等重要器官獲取組織樣本的方式。其一次性使用的自動化設計完美契合了目前對感染控制、工作流程效率和可重複樣本品質的需求。

自動化一次性切片檢查解決方案在技術、工作流程和臨床環境方面發生了變革性轉變

技術、臨床實踐和醫療服務模式的整合正在革新一次性全自動切片檢查設備領域。自動化技術正快速發展，最新的粗針穿刺活體組織切片、細針穿刺切片檢查和真空輔助活體組織切片系統均採用了精密的彈簧加載機制，提高了操作舒適度，並增強了與多種成像平台的兼容性。這些進步降低了操作者差異，保持了檢體品質的一致性，並幫助臨床醫生處理解剖位置複雜、難度較高的病變。

評估美國關稅政策變更對2025年之前一次性自動切片檢查設備的累積影響

美國關稅政策正成為一次性全自動切片檢查設備製造商和經銷商策略規劃的關鍵因素。隨著貿易格局的變化以及2025年新關稅方案的醞釀，企業必須預估醫療設備、零件或原料的額外關稅將如何影響其在這個重要市場中的生產成本、籌資策略和最終定價。

詳細的細分分析揭示了類型、臨床應用、引導方式和最終用戶如何影響切片檢查設備的需求。

從類型、應用、引導方式和終端用戶環境等方面分析，一次性自動切片檢查設備市場呈現清晰的模式。這些模式對於了解創新在哪些領域獲得發展動力以及關鍵手術類別中臨床需求可能發生的變化至關重要。

區域觀點突顯了美洲、歐洲、中東和非洲以及亞太地區在採用模式和戰略機會方面的差異。

區域趨勢將在塑造一次性全自動切片檢查設備市場的機會和決定競爭格局方面發揮重要作用。不同主要地區的醫療保健結構、法規結構、經濟狀況和臨床實踐模式各不相同，這將影響新型切片檢查技術的採用率和優先功能。

主要企業的策略重點在於一次性切片檢查設備的創新、影像整合以及與臨床醫生的協作。

一次性自動切片檢查設備的競爭格局以積極的創新、策略聯盟以及不斷調整產品以適應不斷變化的臨床和影像標準為特徵。主要企業正將其產品組合擴展到粗針穿刺活體組織切片、細針穿刺切片檢查和真空輔助切片檢查等領域，以確保其產品能夠涵蓋乳房、肝臟、肺部和前列腺等部位的手術。同時，他們也在不斷改進設備的人體工學設計、安全功能和影像相容性，以在競爭激烈的市場中脫穎而出。

提高一次性自動切片檢查系統普及率、最佳化產品組合和降低風險的實用策略

一次性全自動切片檢查設備領域的行業領導者可以透過一系列有針對性、可操作的步驟，將當前的市場動態轉化為競爭優勢：優先使產品設計、臨床教育和商業策略與現代癌症診斷和介入治療的實際情況保持一致，同時克服成本壓力、關稅不確定性和區域基礎設施差異。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 一次性全自動切片檢查設備市場（按類型分類）

  • 芯針
    • 自動化核心切片檢查裝置
    • 手動核心針切片裝置
  • 細針穿刺法
    • 多根針
    • 單針
  • 吸力輔助型
    • 手動吸
    • 電動吸盤

第9章 一次性全自動切片檢查設備市場方法指南

  • CT
    • 錐狀射束CT
    • 螺旋CT
  • MRI
    • 封閉式磁振造影
    • 開放式磁振造影
  • 立體定位
    • 框架底座
    • 無框
  • 超音波
    • 2D超音波
    • 3D超音波
    • 多普勒超音波

第10章 按應用分類的一次性全自動切片檢查設備市場

  • 胸部
    • 診斷
    • 篩檢
  • 肝
    • 診斷
    • 治療
  • 肺
    • 診斷
    • 治療
  • 攝護腺
    • 診斷
    • 治療

第11章 按最終用戶分類的一次性全自動切片檢查設備市場

  • 門診手術中心
    • 獨立中心
    • 醫院中心
  • 診所
    • 綜合診所
    • 專科診所
  • 診斷檢查室
    • 醫院檢查室
    • 獨立檢驗機構
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 一次性全自動切片檢查設備市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 一次性全自動切片檢查設備市場（按類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國一次性自動切片檢查設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國一次性自動切片檢查設備市場

第16章：中國一次性全自動切片檢查設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AngioDynamics, Inc.
  • Argon Medical Devices, Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Devicor Medical Products, Inc.
  • FUJIFILM Corporation
  • Hologic, Inc.
  • Johnson & Johnson
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Olympus Corporation
  • Siemens Healthineers AG
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-92740D85F04A

The Disposable Fully Automatic Biopsy Device Market was valued at USD 302.21 million in 2025 and is projected to grow to USD 330.08 million in 2026, with a CAGR of 6.37%, reaching USD 465.93 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 302.21 million
Estimated Year [2026] USD 330.08 million
Forecast Year [2032] USD 465.93 million
CAGR (%) 6.37%

Strategic overview of the disposable fully automatic biopsy device landscape in an era of minimally invasive diagnostics

Disposable fully automatic biopsy devices have emerged as a pivotal enabler of modern, image-guided, minimally invasive diagnostics. As healthcare systems worldwide push toward earlier disease detection, shorter procedure times, and improved patient safety, these devices are transforming how clinicians acquire tissue samples from critical organs such as the breast, liver, lung, and prostate. Their single-use, automated design is particularly well suited to current demands for infection control, workflow efficiency, and reproducible sample quality.

At the same time, the clinical and operational environment surrounding biopsy procedures is becoming more complex. Growing imaging sophistication, expanding screening programs, and heightened patient expectations for comfort and speed are reshaping purchasing criteria in hospitals, ambulatory surgical centers, clinics, and diagnostic laboratories. Against this backdrop, fully automatic biopsy systems must deliver precise needle placement, consistent core or aspirate retrieval, and seamless integration with CT, MRI, stereotactic, and ultrasound guidance.

This executive summary provides a structured view of the evolving market landscape, highlighting transformative technology shifts, policy and tariff implications, and the interplay between product type, clinical application, guidance modality, and end-user setting. It also explores regional dynamics and strategic positioning by leading manufacturers, offering decision-makers a concise yet comprehensive foundation for reassessing their portfolios, partnerships, and investment roadmaps in disposable fully automatic biopsy devices.

Transformational shifts reshaping automated disposable biopsy solutions across technology, workflows, and care settings

The landscape for disposable fully automatic biopsy devices is undergoing a profound transformation driven by converging forces in technology, clinical practice, and healthcare delivery models. Automation is advancing rapidly, with modern core needle, fine needle aspiration, and vacuum assisted systems incorporating refined spring-loading mechanisms, improved actuation ergonomics, and enhanced compatibility with a wide range of imaging platforms. These advances reduce operator variability, support consistent sample quality, and help clinicians manage increasingly complex lesions in challenging anatomical locations.

In terms of device architecture, automated core systems are becoming more compact and lightweight, simplifying manipulation during image-guided procedures and enabling better line-of-sight in crowded interventional suites. Manual core options, while still relevant for certain settings, are increasingly being positioned as cost-sensitive or backup solutions rather than standard of care. Meanwhile, fine needle aspiration systems are evolving from basic single needle designs toward multi-needle configurations that can obtain multiple samples in a single pass, improving diagnostic yield while minimizing procedural trauma and patient discomfort.

Vacuum assisted technologies represent another key shift, particularly in breast and soft-tissue applications where larger or contiguous tissue samples are advantageous. Manual vacuum devices are being refined for greater suction control and safety, whereas motorized vacuum systems integrate programmable suction cycles and automated tissue collection. As a result, clinicians can target smaller lesions with greater confidence, reduce repeat procedures, and provide pathologists with more representative specimens for histopathological and molecular analyses.

At the clinical practice level, there is a decisive move away from open surgical biopsies toward percutaneous, image-guided approaches, aligning with value-based healthcare priorities. In breast care, minimally invasive vacuum assisted and core needle procedures are increasingly employed in both diagnostic and screening pathways, particularly in programs emphasizing early detection. In liver, lung, and prostate indications, growing use of advanced imaging and interventional radiology techniques is expanding the role of automated core and fine needle aspiration devices in both diagnostic and therapeutic contexts.

Simultaneously, integration with imaging guidance is becoming more sophisticated. Cone beam CT and helical CT are enabling real-time or near real-time visualization for complex thoracic and abdominal lesions, while closed MRI and open MRI environments are fueling demand for devices with non-magnetic materials and specialized ergonomics. Stereotactic frame based and frameless techniques, especially in neuro-oncology and certain complex breast procedures, require highly predictable device performance. Ultrasound, including 2D, 3D, and Doppler modalities, remains a workhorse for a wide range of soft-tissue and organ biopsies, prompting manufacturers to optimize needle echogenicity, trajectory visibility, and maneuverability.

Beyond technology, care delivery is shifting toward decentralized and outpatient settings, which is reshaping demand across ambulatory surgical centers, clinics, and diagnostic laboratories. Freestanding ambulatory centers and hospital based centers are expanding procedural volumes as payers encourage migration from inpatient to day-care settings. General practice clinics and specialty clinics are increasingly involved in triaging patients and performing simpler image-guided biopsies, whereas hospital based laboratories and independent laboratories are refining their tissue handling protocols to accommodate higher throughput and more complex analyses.

Collectively, these shifts are creating a more competitive, innovation-driven market environment for disposable fully automatic biopsy devices. Manufacturers are differentiating through advanced ergonomics, pre-loaded sterile configurations, compatibility with diverse imaging modalities, and adjunct features such as integrated depth control, sample capture visualization, and improved safety shields. As clinical guidelines continue to favor minimally invasive biopsy as the diagnostic first-line for many cancers and chronic diseases, the strategic importance of fully automatic, disposable solutions will only deepen.

Assessing the cumulative implications of evolving United States tariff policies on disposable automatic biopsy devices in 2025

Tariff policy in the United States is becoming a significant variable in strategic planning for manufacturers and distributors of disposable fully automatic biopsy devices. As trade dynamics evolve and new tariff schedules are considered for 2025, companies must anticipate how incremental duties on medical devices, components, or raw materials could influence production costs, sourcing strategies, and final pricing in this critical market.

A cumulative effect is emerging, as historical tariffs on metals, polymers, and electronic components intersect with potential adjustments on finished medical products. For automated core needle systems, which often rely on precision-engineered springs, stainless steel or specialty alloy cannulas, and specialized plastics, higher import duties on materials can propagate through the cost structure. Fine needle aspiration devices that use ultra-thin gauge needles, multi-needle configurations, and sophisticated packaging face similar pressures. Vacuum assisted systems, particularly motorized vacuum devices that incorporate electronic controls, motors, and advanced polymers, are especially exposed to tariffs on high-value components.

These cost pressures can affect the pricing and availability of devices used in key applications such as breast, liver, lung, and prostate biopsies. In breast diagnostics and screening, where high procedural volumes meet strong expectations for cost efficiency, tariff-driven price increases may prompt purchasing organizations to renegotiate contracts, seek alternative suppliers, or adjust product mix toward lower-cost options. In liver, lung, and prostate settings, hospital systems and ambulatory centers may respond by standardizing device choices, consolidating vendors, or favoring devices with broader cross-application utility to maximize value.

Furthermore, tariffs influence supply chain configurations for devices utilized under CT, MRI, stereotactic, and ultrasound guidance. Companies may reconsider where they source components such as non-magnetic alloys for MRI-compatible devices, high-visibility needle tips for ultrasound, or specialized materials used in stereotactic instrumentation. Some may opt to localize production or assembly in North America to mitigate tariff exposure, even if this requires upfront capital investments in manufacturing and quality systems.

End users are not insulated from these dynamics. Hospitals, both private and public, along with ambulatory surgical centers, clinics, and diagnostic laboratories, operate under strict budgetary and reimbursement constraints. If tariff-driven cost increases are passed through the supply chain, procurement teams may delay technology upgrades, reduce inventory variety, or prioritize devices that offer the best balance of automation, reliability, and cost. This could favor certain automated core devices or specific fine needle aspiration systems that demonstrate strong clinical performance at moderate price points, while constraining demand for premium, motorized vacuum assisted systems in some settings.

Regulatory and policy considerations add another layer of complexity. While tariffs are mainly trade and fiscal instruments, their indirect effects can intersect with regulatory timelines and compliance costs, especially when production is relocated or when suppliers are switched to circumvent import duties. Companies must ensure that any changes to manufacturing sites, material suppliers, or device configurations maintain adherence to U.S. quality and safety requirements, including rigorous standards for sterility, biocompatibility, and performance.

Looking ahead to 2025, the cumulative impact of tariffs is likely to accelerate strategic moves in sourcing diversification, regional manufacturing, and portfolio optimization. Manufacturers that proactively assess tariff scenarios, model cost implications across core needle, fine needle aspiration, and vacuum assisted offerings, and engage early with U.S. healthcare providers on pricing strategies will be better positioned to maintain competitiveness. In this environment, transparent communication with hospitals, ambulatory centers, clinics, and laboratories about supply reliability and pricing rationale will be essential to preserving trust and long-term partnerships.

Deep segmentation insights reveal how type, clinical application, guidance modality, and end user shape biopsy device demand

The disposable fully automatic biopsy device market exhibits distinct patterns when examined through the lens of type, application, guidance modality, and end-user environment. These patterns are critical for understanding where innovation is gaining traction and how clinical demand is likely to shift within key procedure categories.

From a device type perspective, core needle solutions occupy a pivotal position, bridging the needs of radiology, oncology, and surgical teams. Automated core variants are increasingly favored where precision, repeatability, and integration with imaging guidance are paramount, such as in complex breast and deep-organ biopsies. Manual core devices retain relevance in resource-constrained settings or as backup tools but are gradually being overshadowed by automated counterparts as clinicians prioritize time efficiency and consistent sample volume. Fine needle aspiration devices, available in single needle and multiple needle configurations, are seeing increased adoption in scenarios where cytological assessment is sufficient and tissue architecture is less critical, for example in certain thyroid or lymph node evaluations. Multiple needle designs can obtain several samples in one insertion, which is particularly advantageous for lesions that are small, heterogeneous, or located in anatomically sensitive regions.

Vacuum assisted devices form another crucial segment, offering benefits where obtaining larger or continuous tissue samples improves diagnostic confidence. Manual vacuum systems present a compelling option in environments where cost sensitivity and basic power infrastructure constraints are present, yet clinicians still require enhanced sample retrieval over standard core approaches. Motorized vacuum devices, by contrast, are gaining prominence in advanced breast centers and interventional suites, where programmable suction profiles, automated sample collection, and compatibility with stereotactic and ultrasound guidance contribute to streamlined workflows and reduced procedure times.

Application-based segmentation reveals nuanced trends across organs and clinical pathways. In breast procedures, automated core and vacuum assisted devices are central to both diagnostic and screening programs, supporting minimally invasive management of suspicious lesions detected on mammography, tomosynthesis, or MRI. The dual emphasis on diagnostic confirmation and screening follow-up means that device reliability, patient comfort, and throughput are critical selection criteria. In liver applications, both diagnostic and therapeutic procedures are increasingly guided by fine needle aspiration and automated core systems that must navigate vascular structures and parenchymal variability, often under ultrasound or CT guidance. Clinicians value devices that offer controlled penetration and clear imaging visibility to minimize complication risks.

Lung biopsies highlight the importance of precise needle control under challenging respiratory motion and variable lesion depth, with both diagnostic and therapeutic interventions frequently leveraging fine needle aspiration for peripheral lesions and automated core systems for more solid nodules. Prostate biopsies, which are evolving under the influence of multiparametric MRI and fusion-guided techniques, rely on devices capable of accurate sampling of targeted regions, supporting both initial diagnosis and therapy planning. In these prostate pathways, automated core needles and refined fine needle aspiration devices are expected to align closely with imaging advancements and evolving clinical protocols.

Guidance modality segmentation further clarifies where demand for high-performance disposable devices is strongest. In CT-guided interventions, including cone beam CT and helical CT, devices must maintain stability and visibility during rotational or stepwise imaging sequences. Needle design, including markers and echogenic or radiopaque features, can significantly influence procedural efficiency. MRI-guided biopsies, whether in closed or open MRI systems, drive demand for devices constructed from non-ferromagnetic materials and engineered to minimize artifacts, while also accommodating space constraints within scanners. Stereotactic guidance, spanning frame based and frameless systems, underscores the need for mechanical precision and predictable device deployment, particularly in neurologic and complex breast procedures where millimeter-level accuracy is critical.

Ultrasound-guided biopsies, including those using 2D, 3D, and Doppler ultrasound, remain the most broadly used guidance mode across organ systems. Here, devices that offer excellent sonographic visibility, smooth insertion, and compatibility with real-time adjustments are strongly favored. As 3D and Doppler capabilities expand, there is growing interest in biopsy devices that can integrate with advanced imaging overlays, fusion techniques, and navigation software, thereby improving targeting fidelity for subtle or poorly delineated lesions.

End-user segmentation reveals that hospitals remain the anchor for high-complexity and multidisciplinary procedures, with private hospitals often driving early adoption of advanced automated core and motorized vacuum technologies, and public hospitals emphasizing cost-effectiveness and standardized workflows. Ambulatory surgical centers, including both freestanding centers and hospital based centers, are capturing a growing share of procedures that qualify for same-day discharge, particularly in breast and peripheral organ biopsies. Their procurement decisions tend to emphasize device reliability, rapid turnaround, and predictable per-procedure costs.

Clinics, encompassing general practice clinics and specialty clinics, play a key role in early assessment and triage. Specialty clinics, such as dedicated breast or urology practices, are increasingly equipped to perform targeted biopsies using fine needle aspiration and automated core devices under ultrasound guidance, allowing them to manage a subset of cases without referral to tertiary centers. Diagnostic laboratories, both hospital based and independent, influence device choice indirectly through feedback on sample adequacy and quality. Their emphasis on consistent core size, minimal crush artifacts, and sufficient cellularity informs procurement decisions upstream, driving preference for devices that reliably satisfy histopathological and molecular testing requirements.

Overall, segmentation insights highlight a landscape where clinical sophistication, imaging integration, and care setting characteristics jointly determine which disposable fully automatic biopsy devices gain prominence. Stakeholders who align their product portfolios and commercialization strategies with these segment-specific trends are better positioned to capture emerging demand and support evolving standards of care.

Regional perspectives highlight divergent adoption patterns and strategic opportunities across Americas, EMEA, and Asia-Pacific

Regional dynamics play a decisive role in shaping opportunities and competitive behavior within the disposable fully automatic biopsy device market. Each major geography presents distinct healthcare structures, regulatory frameworks, economic conditions, and clinical practice patterns that influence how quickly new biopsy technologies are adopted and which features are prioritized.

In the Americas, the United States dominates procedural volumes and sets many of the clinical and regulatory benchmarks that influence broader regional adoption. Strong emphasis on early cancer detection, extensive breast screening programs, and sophisticated interventional radiology services sustain demand for advanced automated core, fine needle aspiration, and vacuum assisted devices. Hospitals and ambulatory surgical centers often lead in adopting motorized vacuum systems and MRI-compatible devices, particularly in urban and academic settings. Reimbursement structures, payer policies, and evolving tariff scenarios, however, create nuanced pressures on pricing and vendor selection. In Latin American countries, public healthcare constraints and budget variability tend to favor cost-effective, robust devices, with gradual uptake of more advanced solutions in major metropolitan centers and private institutions.

Across Europe, Middle East, and Africa, diversity in healthcare financing and infrastructure results in a heterogeneous pattern of adoption. In Western Europe, strong regulatory oversight, well-established cancer screening programs, and widespread access to advanced imaging support steady utilization of automated core and vacuum assisted technologies. Hospitals in these markets often maintain rigorous procurement standards, emphasizing clinical evidence, health economic value, and compatibility with CT, MRI, stereotactic, and ultrasound platforms. Central and Eastern European countries exhibit growing interest in upgrading biopsy capabilities, yet face budgetary and infrastructural constraints that can limit rapid deployment of premium devices.

In the Middle East, investment in high-end medical facilities, especially in Gulf states, is fostering demand for modern image-guided biopsy suites equipped with advanced ultrasound, CT, and MRI systems. These environments typically favor state-of-the-art automated core and vacuum assisted devices that align with international best practices. In contrast, many African nations grapple with limited access to imaging modalities and specialized personnel, which constrains the use of fully automatic systems to larger urban hospitals and select private centers. In these settings, basic automated core and fine needle aspiration devices that can function effectively with ultrasound guidance and modest supporting infrastructure play a particularly important role.

The Asia-Pacific region is characterized by rapid growth in healthcare capacity, rising awareness of cancer screening, and a broad disparity between high-resource and resource-limited settings. Developed markets such as Japan, South Korea, Australia, and Singapore demonstrate strong adoption of sophisticated automated core and vacuum assisted systems, supported by robust imaging capabilities and comprehensive reimbursement frameworks. These countries are often early adopters of MRI-guided biopsies, 3D ultrasound-guided procedures, and fusion imaging techniques, which in turn drive demand for disposable devices that integrate seamlessly with advanced guidance technologies.

Emerging economies such as China, India, and Southeast Asian nations are expanding their diagnostic infrastructure, particularly in urban tertiary centers where CT, MRI, and high-quality ultrasound are increasingly available. Here, demand for automated core and fine needle aspiration devices is rising in parallel with upgrades to oncology and interventional radiology services. However, procurement decisions are heavily influenced by cost considerations, supply reliability, and local regulatory requirements. Outside major metropolitan areas, constraints on imaging access and specialized training may slow adoption of more complex vacuum assisted devices, reinforcing the role of simpler, robust automated systems.

Collectively, regional insights underscore that a one-size-fits-all approach is untenable. Manufacturers must tailor product portfolios, pricing strategies, training programs, and distribution models to the specific conditions in the Americas, Europe, Middle East and Africa, and Asia-Pacific. Success depends on understanding how local policies, clinical guidelines, and infrastructure investments influence the balance between core needle, fine needle aspiration, and vacuum assisted devices, as well as the relative roles of hospitals, ambulatory surgical centers, clinics, and laboratories in each region.

Leading company strategies emphasize innovation, imaging integration, and clinician partnerships in disposable biopsy devices

The competitive environment for disposable fully automatic biopsy devices is marked by active innovation, strategic collaborations, and a continual push to align products with evolving clinical and imaging standards. Leading companies are expanding their portfolios across core needle, fine needle aspiration, and vacuum assisted segments, ensuring coverage of applications in breast, liver, lung, and prostate procedures. At the same time, they are refining device ergonomics, safety features, and imaging compatibility to differentiate offerings in a crowded marketplace.

One notable trend among top manufacturers is the drive to enhance automation and user experience in core needle devices. By refining spring mechanisms, trigger systems, and depth-control features, companies are striving to deliver more predictable tissue sampling with fewer misfires and reduced operator fatigue. They are investing in materials and surface treatments that improve needle sharpness and longevity while maintaining sterility and biocompatibility. In parallel, fine needle aspiration devices are being redesigned to accommodate multiple needle options within a single system, enabling clinicians to switch between single needle and multiple needle configurations depending on lesion characteristics and procedural goals.

Vacuum assisted systems represent an area of intense competition, with companies pushing the boundaries of both manual vacuum and motorized vacuum technologies. Manual systems are being positioned as reliable, cost-effective options that still provide meaningful advantages in sample volume and integrity compared with standard core devices. Motorized vacuum devices, on the other hand, are marketed around their ability to deliver controlled, programmable suction, integrated sample retrieval, and smooth coordination with stereotactic, ultrasound, and MRI guidance workflows. Manufacturers are exploring modular designs that support different needle sizes and accessory sets, making it easier for facilities to adapt devices to varied clinical scenarios.

Another key competitive dimension is integration with imaging platforms and guidance systems. Companies recognize that success increasingly depends on how well their devices perform under CT, MRI, stereotactic, and ultrasound guidance, including subsegments such as cone beam CT, helical CT, closed and open MRI, frame based and frameless stereotactic systems, and advanced 2D, 3D, and Doppler ultrasound units. This has prompted collaborations with imaging system vendors, co-development of biopsy targeting kits, and development of needles optimized for visualization and maneuverability under specific imaging conditions.

End-user engagement is also central to competitive positioning. Leading manufacturers work closely with hospitals, ambulatory surgical centers, clinics, and diagnostic laboratories to understand practical workflow constraints and unmet needs. They offer training programs for radiologists, surgeons, pathologists, and technologists, emphasizing correct device usage, optimization of imaging guidance, and best practices for sample handling. Feedback from hospital based laboratories and independent laboratories on sample quality informs iterative device redesigns aimed at improving core consistency, minimizing tissue crush, and ensuring adequate material for histology, immunohistochemistry, and molecular testing.

From a strategic standpoint, companies are balancing global reach with regional customization. They are tailoring device portfolios and pricing structures to the specific demands of the Americas, Europe, Middle East and Africa, and Asia-Pacific, taking into account differences in reimbursement, regulatory pathways, and infrastructure. Some manufacturers are pursuing localized production or assembly to address tariff risks and enhance supply resilience, while others focus on distribution partnerships and service networks to ensure dependable availability and technical support.

In this competitive landscape, success hinges on the ability to anticipate clinical and policy trends, invest in differentiated technology across core needle, fine needle aspiration, and vacuum assisted devices, and cultivate strong relationships with key opinion leaders and purchasing decision-makers. Companies that align their innovation pipelines with emerging needs in breast, liver, lung, and prostate care, and that demonstrate tangible improvements in patient outcomes and workflow efficiency, are poised to solidify their positions in the disposable fully automatic biopsy device market.

Actionable strategies to optimize portfolios, mitigate risks, and accelerate adoption of disposable automatic biopsy systems

Industry leaders in the disposable fully automatic biopsy device space can translate current market dynamics into competitive advantage by taking a series of focused, actionable steps. The priority is to align product design, clinical education, and commercial strategy with the realities of modern cancer diagnostics and interventional practice, while navigating cost pressures, tariff uncertainties, and regional disparities in infrastructure.

First, companies should invest in a balanced product portfolio that spans automated core, fine needle aspiration, and vacuum assisted devices, ensuring coverage of breast, liver, lung, and prostate applications. Within this portfolio, emphasis should be placed on automated core systems and motorized vacuum technologies that integrate seamlessly with CT, MRI, stereotactic, and ultrasound guidance, including cone beam CT, helical CT, closed and open MRI, frame based and frameless stereotactic approaches, and 2D, 3D, and Doppler ultrasound. Developing modular platforms that allow easy switching between single needle and multiple needle configurations, or between manual vacuum and motorized vacuum components, can increase flexibility for hospitals and ambulatory centers.

Second, leaders should prioritize design features that directly address clinician pain points. This includes ergonomics that reduce hand strain and facilitate precise control, enhanced needle visibility under imaging, intuitive actuation mechanisms, and robust safety features to minimize accidental needle exposure or misfire. Close collaboration with radiologists, surgeons, and pathologists can reveal subtle but impactful improvements in device design, from handle geometry and trigger sensitivity to sample capture chambers that preserve tissue integrity.

Third, companies must strengthen their engagement with end users across the continuum of care. Ambulatory surgical centers, both freestanding centers and hospital based centers, need clear value propositions around procedure efficiency and predictable per-case costs. Clinics, including general practice clinics and specialty clinics, benefit from training programs that allow them to safely adopt ultrasound-guided fine needle aspiration or core biopsy for selected cases. Hospital based laboratories and independent laboratories should be integrated into feedback loops to ensure that device performance aligns with emerging needs in molecular diagnostics and personalized medicine. Structured educational initiatives, including workshops and simulation-based training, can accelerate adoption and reduce variability in clinical outcomes.

Fourth, strategic planning should incorporate scenario analysis for tariffs and regulatory changes, particularly for the United States market. Companies ought to map their supply chains for core needle, fine needle aspiration, and vacuum assisted devices to identify vulnerabilities related to raw materials, components, or finished goods. Diversifying suppliers, considering regional manufacturing or assembly, and evaluating alternative materials can help mitigate cost volatility and supply risks. At the same time, any adjustments must maintain compliance with stringent safety, performance, and sterility standards.

Fifth, leaders should tailor commercial strategies to regional realities. In the Americas, emphasis may fall on demonstrating health economic value, aligning with clinical guidelines, and navigating complex payer environments. In Europe, Middle East, and Africa, strategies should account for diverse regulatory frameworks and varying levels of imaging infrastructure, potentially leveraging tiered product lines that align with differing budget constraints. In Asia-Pacific, partnerships with local distributors, participation in training programs, and support for emerging screening initiatives can be critical to building long-term market presence.

Finally, it is vital to leverage data and real-world evidence to differentiate products and support adoption. Collecting and analyzing outcomes data on diagnostic yield, complication rates, procedure times, and sample adequacy across breast, liver, lung, and prostate procedures can validate the clinical benefits of advanced automated core and vacuum assisted systems. Sharing these insights through publications, conference presentations, and collaborative research with leading centers helps bui

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Disposable Fully Automatic Biopsy Device Market, by Type

  • 8.1. Core Needle
    • 8.1.1. Automated Core
    • 8.1.2. Manual Core
  • 8.2. Fine Needle Aspiration
    • 8.2.1. Multiple Needle
    • 8.2.2. Single Needle
  • 8.3. Vacuum Assisted
    • 8.3.1. Manual Vacuum
    • 8.3.2. Motorized Vacuum

9. Disposable Fully Automatic Biopsy Device Market, by Guidance Type

  • 9.1. CT
    • 9.1.1. Cone Beam CT
    • 9.1.2. Helical CT
  • 9.2. MRI
    • 9.2.1. Closed MRI
    • 9.2.2. Open MRI
  • 9.3. Stereotactic
    • 9.3.1. Frame Based
    • 9.3.2. Frameless
  • 9.4. Ultrasound
    • 9.4.1. 2D Ultrasound
    • 9.4.2. 3D Ultrasound
    • 9.4.3. Doppler Ultrasound

10. Disposable Fully Automatic Biopsy Device Market, by Application

  • 10.1. Breast
    • 10.1.1. Diagnostic
    • 10.1.2. Screening
  • 10.2. Liver
    • 10.2.1. Diagnostic
    • 10.2.2. Therapeutic
  • 10.3. Lung
    • 10.3.1. Diagnostic
    • 10.3.2. Therapeutic
  • 10.4. Prostate
    • 10.4.1. Diagnostic
    • 10.4.2. Therapeutic

11. Disposable Fully Automatic Biopsy Device Market, by End User

  • 11.1. Ambulatory Surgical Centers
    • 11.1.1. Freestanding Centers
    • 11.1.2. Hospital Based Centers
  • 11.2. Clinics
    • 11.2.1. General Practice Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Diagnostic Laboratories
    • 11.3.1. Hospital Based Laboratories
    • 11.3.2. Independent Laboratories
  • 11.4. Hospitals
    • 11.4.1. Private Hospital
    • 11.4.2. Public Hospital

12. Disposable Fully Automatic Biopsy Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Disposable Fully Automatic Biopsy Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Disposable Fully Automatic Biopsy Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Disposable Fully Automatic Biopsy Device Market

16. China Disposable Fully Automatic Biopsy Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AngioDynamics, Inc.
  • 17.6. Argon Medical Devices, Inc.
  • 17.7. B. Braun SE
  • 17.8. Becton, Dickinson and Company
  • 17.9. Boston Scientific Corporation
  • 17.10. Cardinal Health, Inc.
  • 17.11. Cook Medical LLC
  • 17.12. Devicor Medical Products, Inc.
  • 17.13. FUJIFILM Corporation
  • 17.14. Hologic, Inc.
  • 17.15. Johnson & Johnson
  • 17.16. Medtronic plc
  • 17.17. Merit Medical Systems, Inc.
  • 17.18. Olympus Corporation
  • 17.19. Siemens Healthineers AG
  • 17.20. Stryker Corporation
  • 17.21. Teleflex Incorporated
  • 17.22. Terumo Corporation
  • 17.23. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GUIDANCE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AUTOMATED CORE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AUTOMATED CORE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AUTOMATED CORE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MANUAL CORE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MANUAL CORE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MANUAL CORE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MULTIPLE NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MULTIPLE NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MULTIPLE NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SINGLE NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SINGLE NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SINGLE NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MANUAL VACUUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MANUAL VACUUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MANUAL VACUUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MOTORIZED VACUUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MOTORIZED VACUUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MOTORIZED VACUUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GUIDANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CONE BEAM CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HELICAL CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HELICAL CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HELICAL CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLOSED MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLOSED MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLOSED MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY OPEN MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY OPEN MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY OPEN MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FRAME BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FRAME BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FRAME BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FRAMELESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FRAMELESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FRAMELESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY 2D ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY 2D ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY 2D ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY 3D ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY 3D ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY 3D ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DOPPLER ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DOPPLER ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DOPPLER ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FREESTANDING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FREESTANDING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FREESTANDING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITAL BASED CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITAL BASED CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITAL BASED CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GUIDANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GUIDANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GUIDANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GUIDANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GUIDANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY LUNG, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY PROSTATE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY VACUUM ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY GUIDANCE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY CT, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY MRI, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY STEREOTACTIC, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST DISPOSABLE FULLY AUTOMATIC BIOPSY DEVICE MARKET SIZE, BY BREAST, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE